Table 1 Basic characteristics of analysed cohort comprising clinical data, therapy and co-morbidities.
From: IAPP - oligomerisation levels in plasma of people with type 2 diabetes
Parameter | Healthy control | T2D without complications | T2D with complications |
|---|---|---|---|
Number | 21 | 13 | 16 |
Age [yrs] | 48.9 ± 7.2 | 56.9 ± 9.9 | 62.9 ± 18.2 |
BMI [kg/m2] | 27.1 ± 4.2 | 28.2 ± 3.6 | 29.8 ± 4.0 |
Diabetes duration [yrs] | 0.0 ± 0.0 | 5.2 ± 4.4 | 16.1 ± 12.5 |
HbA1c [%] | 5.3 ± 0.2 | 7.9 ± 1.2 | 8.4 ± 1.0 |
C-peptide [pmol/l] | 1067 ± 557 | 1275 ± 439 | 1100 ± 832 |
HDL-cholesterol [mg/dl] | 53.0 ± 11.1 | 45.1 ± 8.8 | 44.3 ± 9.3 |
LDL-cholesterol [mg/dl] | 142.4 ± 23.8 | 134.2 ± 48.8 | 93.7 ± 27.4 |
GFR [ml/min] | – | 82.2 ± 13.7 | 78.3 ± 18.8 |
Urine albumine [mg/l] | – | 16.0 ± 18.4 | 75.9 ± 46.8 |
Blood pressure systolic [mm Hg] | – | 128.0 ± 7.0 | 144.0 ± 14.0 |
Blood pressure diastolic [mm Hg] | – | 77.0 ± 8.0 | 84.0 ± 11.0 |
IAPP [pg/ml] | 3701 ± 4771 | 1165 ± 647 | 4906 ± 6457 |
Insulin in mU/l (includes insulin therapy) | 15.2 ± 10.7 | 17.6 ± 27.5 | 33.9 ± 21.5 |
SPISE-INDEX | 5.9 ± 1.5 | 5.1 ± 1.3 | 4.7 ± 1.0 |
Therapy | |||
Insulin (U/day/kg BW) | 0.538 ± 0.219 | ||
Metformin [N] | 10 | 6 | |
SGLT2 [N] | 3 | 4 | |
DPPIV [N] | 6 | 3 | |
Statin [N] | 3 | 10 | |
Omega-3-fatty acids [N] | 4 | 4 | |
Ezetimibe [N] | 1 | 0 | |
Fibrate [N] | 0 | 2 | |
Co-morbidities | |||
Hypertension [N] | 6 | 14 | |
PAD [N] | 0 | 4 | |
CVD [N] | 0 | 5 | |
CAD [N] | 0 | 8 | |
DFU [N] | 0 | 4 | |
